Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

UConn advances re leukemia, Rett syndrome

UConn associate professor of pharmaceutics Xiuling Lu, and professor of chemistry Rajeswari M. Kasi were part of a team that recently found that a commonly-used drug may be...

| By Kelley Gipson

Bioasis advances in crossing blood-brain barrier

Bioasis Technologies has formed a research collaboration with Aposense Limited. Aposense is an Israeli bio-pharmaceutical company specializing in the development of novel drugs utilizing membrane electrical forces...

| By Kelley Gipson

Vanessa Biotech secures orphan drug designation

Vanessa Biotech has secured an orphan drug designation for Shylicine™, the only treatment of its kind developed for microvillus inclusion disorder, a rare and often lethal...

| By Kelley Gipson

Branford-based IsoPlexis sees rapid growth

Nine years ago, a half-dozen professors at Yale and other universities envisioned a life sciences system that would aid researchers and drugmakers in evaluating how...

| By Kelley Gipson

Boehringer Ingelheim steps up investment in R&D

Boehringer Ingelheim, the German pharma giant whose North American headquarters are in Ridgefield, reports that despite the pandemic, it maintained momentum in 2020. The company...

| By Kelley Gipson

IsoPlexis, Hyperfine make ‘top 15’ list

The trade publication Fierce MedTech has chosen both Branford-based Yale spinout IsoPlexis and Guilford-based portable MRI maker Hyperfine Research for its 2020 “Fierce 15.” “Each...

| By Kelley Gipson

CytoVeris extends partnership with Yale

CytoVeris reports the extension of its research partnership with Yale University. The collaboration continues to build and validate an AI-driven ‘smart’ algorithm which serves as the...

| By Kelley Gipson

Simcha receives funding re cancer therapy

Dr. Aaron Ring, an assistant professor of immunobiology at Yale, is piloting a new approach to targeting cancerous tumors that has not only drawn the eyes...

| By Kelley Gipson

Vanessa Research is now Vanessa Biotech

Hamden-based Vanessa Research is changing its name to Vanessa Biotech. The company name remains a tribute to Professor Vanessa Ameen, whose research laid the foundation...

| By Kelley Gipson

BioXcel drug named breakthrough therapy

The FDA has designated a BioXcel drug a “breakthrough therapy” for dementia-related agitation, a label that has the potential to speed up the regulatory review process. BioXcel...